D. Jody

3.4k total citations
23 papers, 1.6k citations indexed

About

D. Jody is a scholar working on Psychiatry and Mental health, Pharmacology and Neurology. According to data from OpenAlex, D. Jody has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 4 papers in Pharmacology and 4 papers in Neurology. Recurrent topics in D. Jody's work include Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (5 papers) and Treatment of Major Depression (4 papers). D. Jody is often cited by papers focused on Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (5 papers) and Treatment of Major Depression (4 papers). D. Jody collaborates with scholars based in United States, Germany and United Kingdom. D. Jody's co-authors include William H. Carson, Jeffrey A. Lieberman, Robert D. McQuade, S. Szymanski, José Alvir, S. Geisler, David Mayerhoff, Mirza W. Ali, Д. Арчибалд and Г. Ингенито and has published in prestigious journals such as JAMA, American Journal of Psychiatry and Neurology.

In The Last Decade

D. Jody

23 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Jody United States	14	922	342	206	204	182	23	1.6k
Arnold E. Merriam United States	15	732 0.8×	284 0.8×	155 0.8×	213 1.0×	80 0.4×	28	1.4k
Pádraig Wright United Kingdom	22	1.0k 1.1×	607 1.8×	571 2.8×	728 3.6×	79 0.4×	45	2.6k
Walter Deberdt United States	25	1.1k 1.2×	44 0.1×	334 1.6×	153 0.8×	214 1.2×	62	1.8k
Philippos Gourzis Greece	21	458 0.5×	180 0.5×	262 1.3×	131 0.6×	47 0.3×	80	1.4k
Elías Ólafsson Iceland	23	2.0k 2.2×	187 0.5×	88 0.4×	366 1.8×	28 0.2×	47	2.6k
Jacqueline Aston Switzerland	26	1.6k 1.7×	57 0.2×	310 1.5×	130 0.6×	103 0.6×	62	2.5k
Taoufik Alsaadi United Arab Emirates	22	810 0.9×	310 0.9×	73 0.4×	216 1.1×	21 0.1×	84	1.4k
José Luís Carrasco Spain	26	361 0.4×	65 0.2×	607 2.9×	60 0.3×	236 1.3×	127	2.2k
Evangelia Kararizou Greece	21	471 0.5×	287 0.8×	127 0.6×	344 1.7×	42 0.2×	106	1.5k
Rebekah M. Ahmed Australia	30	746 0.8×	82 0.2×	105 0.5×	1.6k 7.8×	128 0.7×	123	3.0k

Countries citing papers authored by D. Jody

Since Specialization

Citations

This map shows the geographic impact of D. Jody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Jody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Jody more than expected).

Fields of papers citing papers by D. Jody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Jody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Jody. The network helps show where D. Jody may publish in the future.

Co-authorship network of co-authors of D. Jody

This figure shows the co-authorship network connecting the top 25 collaborators of D. Jody. A scholar is included among the top collaborators of D. Jody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Jody. D. Jody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Havrdová, Eva, Douglas L. Arnold, Jeffrey Cohen, et al.. (2017). Alemtuzumab CARE-MS I 5-year follow-up. Neurology. 89(11). 1107–1116. 176 indexed citations

Coles, Alasdair, JA Cohen, Gavin Giovannoni, et al.. (2017). Alemtuzumab CARE-MS II 5-year follow-up. Apollo (University of Cambridge). 6 indexed citations

Coles, Alasdair, Jeffrey Cohen, Edward Fox, et al.. (2017). Alemtuzumab CARE-MS II 5-year follow-up. Neurology. 89(11). 1117–1126. 212 indexed citations

Tandon, Rajiv, Robert F. DeVellis, Hong Li, et al.. (2005). Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research. 136(2-3). 211–221. 33 indexed citations

Rush, A. John, Madhukar H. Trivedi, Thomas Carmody, et al.. (2004). Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients. Neuropsychopharmacology. 30(2). 405–416. 107 indexed citations

Modell, S., D. Jody, M. Kujawa, et al.. (2004). P.2.076 Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotics. European Neuropsychopharmacology. 14. S265–S265. 4 indexed citations

Casey, Daniel E., William H. Carson, Anutosh Ranjan Saha, et al.. (2003). Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 166(4). 391–399. 207 indexed citations

McQuade, Robert D., D. Jody, John M. Kane, et al.. (2003). P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. European Neuropsychopharmacology. 13. S326–S326. 7 indexed citations

Kostić, Dušan, George Manos, Elyse Stock, et al.. (2003). P.2.111 Long-term effects of aripirazole on the negative symptoms of schizophrenia. European Neuropsychopharmacology. 13. S328–S328. 7 indexed citations

10.

Kujawa, M., et al.. (2003). Switching to aripiprazole monotherapy. Schizophrenia Research. 60(1). 290–290. 10 indexed citations

11.

Stock, Eveline O., S.R. Marder, D. Jody, et al.. (2003). P.2.108 Plasma lipids levels and glycemic control in long-term treatment with aripiprazole. European Neuropsychopharmacology. 13. S327–S327. 8 indexed citations

12.

Marcus, R., et al.. (2002). Aripiprazole versus placebo in acute mania. European Neuropsychopharmacology. 12. 289–289. 13 indexed citations

13.

Ferguson, James M., Ram Shrivastava, Stephen M. Stahl, et al.. (2001). Reemergence of Sexual Dysfunction in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 62(1). 24–29. 83 indexed citations

14.

Bilder, Robert M., B. Bogerts, Manzar Ashtari, et al.. (1995). Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophrenia Research. 17(1). 47–58. 159 indexed citations

15.

Szymanski, S., Jeffrey A. Lieberman, José Alvir, et al.. (1995). Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry. 152(5). 698–703. 255 indexed citations

16.

Levy, Deborah L., Melissa J. Smith, Delbert G. Robinson, et al.. (1993). Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biological Psychiatry. 34(8). 507–514. 39 indexed citations

17.

Levy, Deborah L., B. Bogerts, Gustav Degreef, et al.. (1992). Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia. Schizophrenia Research. 8(1). 1–10. 15 indexed citations

18.

Loebel, A., J.A. Lieberman, David Mayerhoff, et al.. (1991). Correlates of course and outcome in first-episode schizophrenia. Schizophrenia Research. 4(3). 290–290. 3 indexed citations

19.

Jody, D., et al.. (1990). Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia.. PubMed. 26(2). 224–30. 25 indexed citations

20.

Lieberman, J.A., et al.. (1989). Treatment outcome of first episode schizophrenia.. PubMed. 25(1). 92–6. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact